Tekla Life Sciences Investors (HQL)

$13.59

-0.22 (-1.59%)
Rating:
Recommendation:
-
Symbol HQL
Price $13.59
Beta 0.825
Volume Avg. 0.07M
Market Cap 341.707M
Shares () -
52 Week Range 13.03-21.64
1y Target Est -
DCF Unlevered HQL DCF ->
DCF Levered HQL LDCF ->
ROE 1.67% Neutral
ROA 1.81% Neutral
Operating Margin -
Debt / Equity 2.97% Neutral
P/E -
P/B 0.73 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest HQL news


Financial Services
Asset Management
New York Stock Exchange

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.